Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study
Sponsor: |
Columbia University |
Enrolling: |
Male and Female Patients |
Study Length: |
7 Weeks |
Clinic Visits: |
2 |
IRB Number: |
AAAR3505 |
U.S. Govt. ID: |
NCT03473665 |
Contact: |
Christopher Depender: 212-305-4114 / cd2686@cumc.columbia.edu |
This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks. Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and exclusion criteria will be randomized into one of the four arms after an initial one week washout period, including: 1) indomethacin 75mg Q12H; 2) diclofenac 75mg Q12H; 3) meloxicam 7.5mg Q12H; 4) celecoxib 200mg Q12H. The treatment length will be 6 weeks. Primary outcome is the change of pain score from baseline to week 4 and to week 6.
This study is closed
Investigator
Runsheng Wang, MD
A clinical diagnosis of ankylosing spondylitis (AS) by treating rheumatologists |
Yes |
No |
Are taking NSAIDs on a regular basis for AS or axSpA (defined as more than 20 days in the past month) |
Yes |
No |
Concomitant anti-rheumatic drugs are allowed, if the dose has been stable for the past three months |
Yes |
No |
Patients who have concurrent rheumatic diseases other than AS or axSpA |
Yes |
No |
Patients who have oral corticosteroid in the past two weeks |
Yes |
No |